Drugs interactions for Farxiga®

  • 0 Major drug interactions
  • 291 Moderate drug interactions (including ingredients like Acarbose, Acebutolol, Acetylsalicylic acid)
  • 121 Minor drug interactions (including ingredients like Abaloparatide, Acetazolamide, Acetyl sulfisoxazole)
412 interactions for Farxiga®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Farxiga®.
Acarbose
Dapagliflozin may increase the hypoglycemic activities of Acarbose.
Acebutolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acebutolol.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dapagliflozin.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dapagliflozin.
Alogliptin
Dapagliflozin may increase the hypoglycemic activities of Alogliptin.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Dapagliflozin.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Amiodarone
The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Dapagliflozin.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Dapagliflozin.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dapagliflozin.
Amobarbital
Amobarbital may increase the hypotensive activities of Dapagliflozin.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Dapagliflozin.
Aripiprazole
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Aripiprazole.
Arsenic trioxide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Articaine.
Asenapine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Asenapine.
Atazanavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Atazanavir.
Atenolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Atenolol.
Baclofen
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Baclofen.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Dapagliflozin.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Dapagliflozin.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Dapagliflozin.
Bendroflumethiazide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bendroflumethiazide.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Dapagliflozin.
Betaxolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Betaxolol.
Bexagliflozin
Dapagliflozin may increase the hypoglycemic activities of Bexagliflozin.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Dapagliflozin.
Bisoprolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bisoprolol.
Brexpiprazole
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Brexpiprazole.
Bromocriptine
Dapagliflozin may increase the hypoglycemic activities of Bromocriptine.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Dapagliflozin.
Bumetanide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bumetanide.
Butalbital
Butalbital may increase the hypotensive activities of Dapagliflozin.
Canagliflozin
Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.
Cannabidiol
The metabolism of Dapagliflozin can be decreased when combined with Cannabidiol.
Captopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Captopril.
Carvedilol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Carvedilol.
Ceritinib
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ceritinib.
Chlorothiazide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorothiazide.
Chlorpromazine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorthalidone.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Dapagliflozin.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Dapagliflozin.
Ciprofloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ciprofloxacin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dapagliflozin.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Dapagliflozin.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Dapagliflozin.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Dapagliflozin.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Dapagliflozin.
Clozapine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Clozapine.
Conjugated estrogens
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Conjugated estrogens.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Dapagliflozin.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Dapagliflozin.
Dabrafenib
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dabrafenib.
Danazol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Danazol.
Darunavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Darunavir.
Deferasirox
The metabolism of Dapagliflozin can be decreased when combined with Deferasirox.
Deflazacort
The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Dapagliflozin.
Delafloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Delafloxacin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Dapagliflozin.
Desogestrel
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Desogestrel.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Dapagliflozin.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Dapagliflozin.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Dapagliflozin.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dapagliflozin.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Dapagliflozin.
Diazoxide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Diazoxide.
Dienogest
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dienogest.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dapagliflozin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Dapagliflozin.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dapagliflozin.
Diltiazem
The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Dapagliflozin.
Disopyramide
Dapagliflozin may increase the hypoglycemic activities of Disopyramide.
Doxepin
Doxepin may decrease the hypoglycemic activities of Dapagliflozin.
Drospirenone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Drospirenone.
Dulaglutide
Dapagliflozin may increase the hypoglycemic activities of Dulaglutide.
Eltrombopag
The metabolism of Dapagliflozin can be decreased when combined with Eltrombopag.
Empagliflozin
Dapagliflozin may increase the hypoglycemic activities of Empagliflozin.
Enalapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Enalapril.
Enalaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Enalaprilat.
Epinephrine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Epinephrine.
Ertugliflozin
Dapagliflozin may increase the hypoglycemic activities of Ertugliflozin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Dapagliflozin.
Estetrol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estetrol.
Estradiol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estradiol.
Estrone sulfate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estrone sulfate.
Etacrynic acid
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etacrynic acid.
Ethanol
Ethanol may increase the hypotensive activities of Dapagliflozin.
Ethinylestradiol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinylestradiol.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Dapagliflozin.
Ethynodiol diacetate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etonogestrel.
Everolimus
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Everolimus.
Exenatide
Dapagliflozin may increase the hypoglycemic activities of Exenatide.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Dapagliflozin.
Fluconazole
The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Fluconazole.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Dapagliflozin.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Dapagliflozin.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Dapagliflozin.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Dapagliflozin.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Dapagliflozin.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Dapagliflozin.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Dapagliflozin.
Fluticasone furoate
The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Dapagliflozin.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Dapagliflozin.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Dapagliflozin.
Fosamprenavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Fosamprenavir.
Fosinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Fosinopril.
Fosphenytoin
The metabolism of Dapagliflozin can be decreased when combined with Fosphenytoin.
Furosemide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Furosemide.
Gatifloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gatifloxacin.
Gemifloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gemifloxacin.
Glimepiride
Dapagliflozin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Dapagliflozin may increase the hypoglycemic activities of Glipizide.
Glyburide
Dapagliflozin may increase the hypoglycemic activities of Glyburide.
Goserelin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dapagliflozin.
Haloperidol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Haloperidol.
Histrelin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Histrelin.
Hydrochlorothiazide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrochlorothiazide.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Dapagliflozin.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Dapagliflozin.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Dapagliflozin.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Dapagliflozin.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Dapagliflozin.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Dapagliflozin.
Hydroflumethiazide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydroflumethiazide.
Hydroxychloroquine
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
Iloperidone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Iloperidone.
Imipramine
Imipramine may decrease the hypoglycemic activities of Dapagliflozin.
Indapamide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Indapamide.
Indinavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Indinavir.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Dapagliflozin.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Insulin aspart is combined with Dapagliflozin.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Insulin degludec is combined with Dapagliflozin.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Dapagliflozin.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Dapagliflozin.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Insulin glulisine is combined with Dapagliflozin.
Insulin human
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Dapagliflozin.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Dapagliflozin.
Isocarboxazid
Isocarboxazid may increase the orthostatic hypotensive activities of Dapagliflozin.
Isoniazid
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Isoniazid.
Isradipine
The risk or severity of hypoglycemia can be increased when Isradipine is combined with Dapagliflozin.
Labetalol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Labetalol.
Lanreotide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide.
Leuprolide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Dapagliflozin.
Levofloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Levofloxacin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dapagliflozin.
Levonorgestrel
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levonorgestrel.
Linagliptin
Dapagliflozin may increase the hypoglycemic activities of Linagliptin.
Linezolid
Linezolid may increase the orthostatic hypotensive activities of Dapagliflozin.
Liothyronine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Liothyronine.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dapagliflozin.
Liraglutide
Dapagliflozin may increase the hypoglycemic activities of Liraglutide.
Lisinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Lisinopril.
Lithium carbonate
The serum concentration of Lithium carbonate can be decreased when it is combined with Dapagliflozin.
Lithium citrate
The serum concentration of Lithium citrate can be decreased when it is combined with Dapagliflozin.
Lixisenatide
Dapagliflozin may increase the hypoglycemic activities of Lixisenatide.
Lomefloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Lomefloxacin.
Lonapegsomatropin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lonapegsomatropin.
Lopinavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lopinavir.
Lurasidone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lurasidone.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Dapagliflozin.
Mecasermin
Dapagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dapagliflozin.
Mefenamic acid
The metabolism of Dapagliflozin can be decreased when combined with Mefenamic acid.
Megestrol acetate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Megestrol acetate.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Dapagliflozin.
Methohexital
Methohexital may increase the hypotensive activities of Dapagliflozin.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dapagliflozin.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Dapagliflozin.
Methylene blue
Methylene blue may increase the orthostatic hypotensive activities of Dapagliflozin.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Dapagliflozin.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Dapagliflozin.
Metolazone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Metolazone.
Metoprolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Metoprolol.
Mifepristone
Dapagliflozin may increase the hypoglycemic activities of Mifepristone.
Miglitol
Dapagliflozin may increase the hypoglycemic activities of Miglitol.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Dapagliflozin.
Moexipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Moexipril.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Dapagliflozin.
Moxifloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.
Nadolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nadolol.
Nateglinide
Dapagliflozin may increase the hypoglycemic activities of Nateglinide.
Nebivolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nebivolol.
Nefazodone
The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Dapagliflozin.
Nelfinavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Nelfinavir.
Niacin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Niacin.
Nicardipine
The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Dapagliflozin.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Dapagliflozin.
Nilotinib
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Nilotinib.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Dapagliflozin.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Dapagliflozin.
Norethisterone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Norgestimate.
Nortriptyline
Nortriptyline may decrease the hypoglycemic activities of Dapagliflozin.
Octreotide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.
Ofloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ofloxacin.
Olanzapine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Olanzapine.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Dapagliflozin.
Paliperidone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Paliperidone.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Dapagliflozin.
Pasireotide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pasireotide.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.
Pentamidine
Dapagliflozin may increase the hypoglycemic activities of Pentamidine.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Dapagliflozin.
Perindopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Perindopril.
Phenelzine
Phenelzine may increase the orthostatic hypotensive activities of Dapagliflozin.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Dapagliflozin.
Phentermine
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Phentermine.
Phenytoin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Phenytoin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Dapagliflozin.
Pindolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pindolol.
Pioglitazone
Dapagliflozin may increase the hypoglycemic activities of Pioglitazone.
Polythiazide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Polythiazide.
Pramlintide
Dapagliflozin may increase the hypoglycemic activities of Pramlintide.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Dapagliflozin.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Dapagliflozin.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Dapagliflozin.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Dapagliflozin.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Dapagliflozin.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Dapagliflozin.
Primidone
Primidone may increase the hypotensive activities of Dapagliflozin.
Procaine
Procaine may increase the orthostatic hypotensive activities of Dapagliflozin.
Procarbazine
Procarbazine may increase the orthostatic hypotensive activities of Dapagliflozin.
Progesterone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Progesterone.
Propafenone
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Propafenone.
Propranolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Propranolol.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Dapagliflozin.
Pseudoephedrine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pseudoephedrine.
Quetiapine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Quinapril.
Quinine
Dapagliflozin may increase the hypoglycemic activities of Quinine.
Ramipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Ramipril.
Rasagiline
Rasagiline may increase the orthostatic hypotensive activities of Dapagliflozin.
Regorafenib
The metabolism of Dapagliflozin can be decreased when combined with Regorafenib.
Repaglinide
Dapagliflozin may increase the hypoglycemic activities of Repaglinide.
Rifampin
The metabolism of Dapagliflozin can be decreased when combined with Rifampicin.
Ritonavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ritonavir.
Rosiglitazone
Dapagliflozin may increase the hypoglycemic activities of Rosiglitazone.
Safinamide
Safinamide may increase the orthostatic hypotensive activities of Dapagliflozin.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Saquinavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Saquinavir.
Secobarbital
Secobarbital may increase the hypotensive activities of Dapagliflozin.
Selegiline
Selegiline may increase the orthostatic hypotensive activities of Dapagliflozin.
Semaglutide
Dapagliflozin may increase the hypoglycemic activities of Semaglutide.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Dapagliflozin.
Sirolimus
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sirolimus.
Sitagliptin
Dapagliflozin may increase the hypoglycemic activities of Sitagliptin.
Sodium ferric gluconate complex
The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Dapagliflozin.
Somapacitan
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Somapacitan.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Dapagliflozin.
Somatrogon
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Somatrogon.
Sorafenib
The metabolism of Dapagliflozin can be decreased when combined with Sorafenib.
Sotagliflozin
Dapagliflozin may increase the hypoglycemic activities of Sotagliflozin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Dapagliflozin.
Sulfadiazine
Dapagliflozin may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Dapagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Dapagliflozin.
Sunitinib
Dapagliflozin may increase the hypoglycemic activities of Sunitinib.
Tacrolimus
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tacrolimus.
Temsirolimus
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Temsirolimus.
Teprotumumab
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Teprotumumab.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Dapagliflozin.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Dapagliflozin.
Timolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Timolol.
Tipranavir
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tipranavir.
Tirzepatide
Dapagliflozin may increase the hypoglycemic activities of Tirzepatide.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Dapagliflozin.
Tolazamide
Dapagliflozin may increase the hypoglycemic activities of Tolazamide.
Torasemide
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Torasemide.
Trandolapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Trandolapril.
Tranylcypromine
Tranylcypromine may increase the orthostatic hypotensive activities of Dapagliflozin.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Dapagliflozin.
Trimipramine
Trimipramine may decrease the hypoglycemic activities of Dapagliflozin.
Triptorelin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Dapagliflozin.
Trovafloxacin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Trovafloxacin.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dapagliflozin.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dapagliflozin.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Dapagliflozin.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Dapagliflozin.
Verapamil
The risk or severity of hypoglycemia can be increased when Verapamil is combined with Dapagliflozin.
Vorinostat
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Vorinostat.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Dapagliflozin.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Dapagliflozin.
Ziprasidone
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ziprasidone.
Zonisamide
The risk or severity of hypoglycemia can be increased when Zonisamide is combined with Dapagliflozin.
Abaloparatide
The risk or severity of adverse effects can be increased when Abaloparatide is combined with Dapagliflozin.
Acetazolamide
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acetazolamide.
Acetyl sulfisoxazole
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Albuterol
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Albuterol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.
Aliskiren
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.
Ambrisentan
Dapagliflozin may increase the hypotensive activities of Ambrisentan.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.
Aprocitentan
Dapagliflozin may increase the hypotensive activities of Aprocitentan.
Aripiprazole lauroxil
Aripiprazole lauroxil may increase the hypotensive activities of Dapagliflozin.
Avanafil
The risk or severity of hypotension can be increased when Avanafil is combined with Dapagliflozin.
Azilsartan medoxomil
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
Bosentan
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bosentan.
Bretylium
The risk or severity of adverse effects can be increased when Bretylium is combined with Dapagliflozin.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.
Candesartan cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dapagliflozin.
Celecoxib
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Celecoxib.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Dapagliflozin.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Dapagliflozin.
Dasiglucagon
Dapagliflozin may increase the hypotensive activities of Dasiglucagon.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.
Diclofenamide
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Dapagliflozin.
Dinutuximab
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.
Doxazosin
The risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.
Duloxetine
The risk or severity of orthostatic hypotension and syncope can be increased when Dapagliflozin is combined with Duloxetine.
Eplerenone
The risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dapagliflozin.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.
Fedratinib
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Fedratinib.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Dapagliflozin.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.
Fostamatinib
The risk or severity of hypotension can be increased when Fostamatinib is combined with Dapagliflozin.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Dapagliflozin.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Dapagliflozin.
Isosorbide dinitrate
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Dapagliflozin.
Isosorbide mononitrate
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Dapagliflozin.
Isoxsuprine
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.
Ketotifen
The risk or severity of thrombocytopenia can be increased when Dapagliflozin is combined with Ketotifen.
Landiolol
Dapagliflozin may increase the hypotensive activities of Landiolol.
Levodopa
The risk or severity of hypotension and orthostatic hypotension can be increased when Dapagliflozin is combined with Levodopa.
Levothyroxine
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levothyroxine.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Dapagliflozin.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.
Macitentan
Dapagliflozin may increase the hypotensive activities of Macitentan.
Mannitol
The risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Dapagliflozin.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Dapagliflozin.
Metyrosine
Dapagliflozin may increase the hypotensive activities of Metyrosine.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.
Mitapivat
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mitapivat.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Dapagliflozin.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Dapagliflozin.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dapagliflozin.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.
Nitrous acid
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Nitrous acid.
Obinutuzumab
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Obinutuzumab.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.
Opicapone
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Opicapone.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Dapagliflozin.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Dapagliflozin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin.
Papaverine
The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Dapagliflozin.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Dapagliflozin.
Prazosin
The risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.
Probenecid
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Probenecid.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Dapagliflozin.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Dapagliflozin.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.
Riociguat
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.
Risperidone
Dapagliflozin may increase the hypotensive activities of Risperidone.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Dapagliflozin.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapagliflozin.
Rosuvastatin
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rosuvastatin.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Dapagliflozin.
Sacubitril
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sacubitril.
Selexipag
Dapagliflozin may increase the hypotensive activities of Selexipag.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapagliflozin.
Sildenafil
The risk or severity of hypotension can be increased when Sildenafil is combined with Dapagliflozin.
Sotatercept
Dapagliflozin may increase the hypotensive activities of Sotatercept.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Dapagliflozin.
Sulfamethizole
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethizole.
Sumatriptan
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sumatriptan.
Tadalafil
Dapagliflozin may increase the hypotensive activities of Tadalafil.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Dapagliflozin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.
Terazosin
The risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.
Testosterone
Testosterone may increase the hypoglycemic activities of Dapagliflozin.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Dapagliflozin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Dapagliflozin.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.
Tocopherylquinone
Dapagliflozin may increase the hypotensive activities of Tocopherylquinone.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Dapagliflozin.
Treprostinil
Dapagliflozin may increase the hypotensive activities of Treprostinil.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.
Valdecoxib
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Valdecoxib.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.
Vardenafil
The risk or severity of hypotension can be increased when Vardenafil is combined with Dapagliflozin.
Vemurafenib
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Vemurafenib.
Vericiguat
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Vericiguat.